| Literature DB >> 34867792 |
Xueqing Zheng1,2, He Wang1,2, Wentai Zhang1, Shanshan Feng1, Yifan Liu1,2, Shuo Li1, Xinjie Bao1, Lin Lu3, Huijuan Zhu3, Ming Feng1, Renzhi Wang1.
Abstract
Purpose: Cushing's disease (CD) is a rare disease that contributes to 70-80% hypercortisolemia, which presents similarities and differences between pediatric and adult patients, and even between male and female patients. However, the comparative study of CD between different age groups and different genders is still insufficient. The aim of the study is to make a systematic comparison to reveal the gender differences in children and adult patients of CD, helping clinicians to provide optimal treatment for different groups of patients.Entities:
Keywords: Cushing’s disease; adrenocorticotrophin hormone; cortisol; pediatric; transsphenoidal pituitary surgery
Mesh:
Year: 2021 PMID: 34867792 PMCID: PMC8640923 DOI: 10.3389/fendo.2021.749246
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Basic information of pediatric and adult-onset CD.
| Pediatric CD patients (n = 30) | Adult CD patients (n = 392) |
| |
|---|---|---|---|
|
| 15:15 | 326:66 |
|
|
| 15.0 (17.0–11.5) | 38.5 (48.0–30.0) | |
|
| 12.0 (14.3–9.0) | 33.0 (43.0–26.0) | |
|
| 1.7 (3.0–1.2) | 3.0 (7.0–1.8) |
|
|
| 26 (87) | 326 (83) | 0.80 |
|
| 30 (100) | 387 (99) | 1 |
|
| 14 (74) | 237 (81) | 0.55 |
|
| 2 (7) | 23 (6) | 0.70 |
|
| 0 (0) | 16 (4) | 0.62 |
|
| 24 (80) | 293 (76) | 0.60 |
|
| 22 (79) | 274 (79) | 0.99 |
|
| 3 (11)a | 22 (6) | 0.42 |
aThe three recurrent pediatric CD patients were all male.
The bolded values showed the significant results (P < 0.05). No other significant meanings were related
Clinical examinations of pediatric and adult-onset CD.
| Pediatric CD patients (n = 30) | Adult CD patients (n = 392) |
| |
|---|---|---|---|
|
| 23 (77) | 301 (77) | 0.93 |
|
| 23 (77) | 289 (74) | 0.76 |
|
| 28 (97) | 370 (98) | 0.53 |
|
| 21 (95) | 271 (97) | 0.50 |
|
| 26 (93) | 291 (86) | 0.56 |
|
| 16 (53) | 235 (60) | 0.48 |
|
| 15 (94) | 227 (96) | 0.49 |
|
| 12 (75) | 215 (91) | 0.054 |
|
| 15 (94) | 224 (95) | 0.56 |
|
| 5 (45) | 94 (46) | 0.97 |
|
| 30 (100) | 385 (98) | 1 |
|
| 26a (87) | 361 (94) | 0.13 |
|
| 19 (79) | 256 (72) | 0.44 |
|
| 14 (74) | 237 (81) | 0.55 |
|
| 12 (75) | 245 (89) | 0.10 |
|
| 2 (7) | 23 (6) | 0.70 |
|
| 3 (12) | 6 (2) |
|
|
| 1 (33) | 6 (100) | 0.083 |
|
| 1 (50) | 6 (32) | 1 |
|
| 26 (87) | 340 (87) | 1 |
|
| 7 (25) | 101 (27) | 0.79 |
aOther four pediatric patients who were MRI negative were all male.
F, serum cortisol.
The bolded values showed the significant results (P < 0.05). No other significant meanings were related.
Figure 1Clinical manifestations in pediatric and adult-onset CD. *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 2Clinical manifestations between males and females in pediatric patients. *P < 0.05, ** P < 0.01, *** P < 0.001.
Figure 3Clinical manifestations between males and females in adult patients. *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 4Gender-related laboratory investigation tests in pediatric and adult-onset CD. The parameters of PA activity, (A) 8 a.m. ACTH, and (B) 24-h UFC, were significantly higher for adult male patients. The levels of (C) serum potassium, (D) testosterone, and (E) ALT were also significantly higher for males in both pediatric and adult patients. (F) BMI was significantly higher for male patients in children. MP, male pediatric patients; FP, female pediatric patients; MA, male adult patients; FA, female adult patients. (*P < 0.05, **P < 0.01, ***P < 0.001).
Comparison of investigations of the PA axis between microadenoma and macroadenoma.
| 8 a.m. ACTH (μg/dl) | 8 a.m. F (μg/dl) | 8 a.m. ACTH/F | 24-h UFC (μg/d) | |
|---|---|---|---|---|
|
| 70.9 (86.1–74.3) | 26.9 (31.5–26.6) | 2.71 (3.81–1.81) | 491.8 (806.4–579.3) |
|
| 87.3 (106.1–81.7) | 26.0 (30.9–25.1) | 3.06 (4.52–2.31) | 429.0 (767.5–490.5) |
|
|
| 0.78 |
| 0.61 |
The bolded values showed the significant results (P < 0.05). No other significant meanings were related.
Correlation (rs) between indicators of the PA axis and other laboratory investigation results.
| Patient classification | Indicators of PA axis | WBC | RBC | ALT | AST | K | Lymphocyte | B cell | T cell | CD4+ T | CD8+ T | CD4+ T/CD8+ T ratio | BMI | Testosterone |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| 8 a.m. ACTH | 0.352 | −0.158 | 0.091 | −0.143 | −0.586* | −0.790** | −0.663* | −0.547 | −0.626 | −0.182 | −0.438 | 0.070 | 0.344 |
| 8 a.m. F | 0.121 | 0.174 | 0.022 | 0.002 | −0.291 | −0.600 | 0.079 | −0.697* | −0.467 | −0.467 | −0.212 | 0.000 | −0.014 | |
| 24-h UFC | 0.538* | 0.297 | −0.059 | −0.229 | −0.138 | −0.527 | −0.297 | −0.345 | −0.285 | −0.455 | 0.006 | 0.293 | −0.215 | |
|
| 8 a.m. ACTH | 0.077 | 0.088 | 0.548 | −0.186 | 0.033 | −0.500 | 0.143 | −0.500 | −0.238 | −0.333 | −0.048 | −0.118 | 0.564 |
| 8 a.m. F | 0.396 | 0.148 | −0.096 | 0.095 | −0.215 | 0.643 | 0.143 | 0.595 | 0.143 | 0.571 | −0.238 | 0.129 | 0.064 | |
| 24-h UFC | 0.105 | 0.245 | 0.375 | −0.105 | −0.632* | −0.179 | −0.200 | −0.107 | −0.643 | 0.143 | −0.786* | 0.002 | 0.164 | |
|
| 8 a.m. ACTH | 0.008 | −0.170 | 0.457** | 0.243 | −0.407** | −0.367* | 0.028 | −0.373* | −0.392* | −0.266 | −0.218 | 0.041 | −0.222 |
| 8 a.m. F | 0.246 | −0.139 | 0.449** | 0.213 | −0.380** | −0.023 | 0.282 | −0.031 | −0.099 | −0.081 | −0.245 | 0.035 | −0.211 | |
| 24-h UFC | 0.014 | −0.206 | 0.437** | 0.230 | −0.456** | −0.073 | 0.320 | −0.117 | −0.119 | −0.020 | −0.219 | −0.144 | −0.233 | |
|
| 8 a.m. ACTH | −0.083 | −0.180** | 0.093 | 0.080 | −0.145** | −0.155 | 0.031 | −0.153 | −0.211 | −0.060 | −0.182* | −0.094 | 0.033 |
| 8 a.m. F | 0.013 | −0.174** | 0.136* | 0.051 | −0.244** | −0.214** | −0.017 | −0.235** | −0.321** | −0.148 | −0.160* | −0.123* | 0.118* | |
| 24-h UFC | 0.017 | −0.208** | 0.126* | −0.028 | −0.189** | −0.152 | 0.027 | −0.134 | −0.203* | −0.005 | −0.204* | −0.197** | 0.016 |
*Correlation is significant at the 0.05 level.
**Correlation is significant at the 0.01 level.
Prognosis of patients treated with TSS.
| Immediate remission (%) | Long-term remission (%) | Recurrence (%) | |
|---|---|---|---|
|
| 280 (77) | 264 (79) | 20 (6) |
|
| 25 (66) | 21 (68) | 3 (10) |
|
| 0.14 | 0.14 | 0.43 |
|
| 203 (81) | 45 (80) | 4 (7) |
|
| 39 (66) | 182 (78) | 16 (7) |
|
|
| 0.75 | 1 |
|
| 8 (0.35) | 15 (68) | 1 (5) |
|
| 310 (79) | 273 (79) | 24 (7) |
|
|
| 0.28 | 1 |
|
| 3 (33) | 6 (75) | 0 (0) |
|
| 259 (77) | 243 (80) | 17 (6) |
|
|
| 0.67 | 1 |
|
| 283 (79) | 247 (79) | 21 (7) |
|
| 34 (50) | 49 (78) | 4 (6) |
|
|
| 0.88 | 1 |
|
| 76 (70) | 74 (77) | 5 (5) |
|
| 228 (79) | 203 (78) | 19 (7) |
|
|
| 0.84 | 0.48 |
The bolded values showed the significant results (P < 0.05). No other significant meanings were related.